Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMc1900712 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pancreatic carcinoma is a prognostically unfavorable cancer disease with growing incidence and mortality, which is the 3rd most common cause of cancer-related death in developed countries. The 5-year survival rate does not exceed 11% and is the lowest across all cancer diagnoses. Only about 20-30% of patients have resectable (RPC) or borderline resectable (BRPC) disease at the time of diagnosis.
View Article and Find Full Text PDFSurvival Outcomes and Genetic Characteristics of Resected Pancreatic Acinar Cell Carcinoma.
Ann Surg Oncol
November 2024
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Background: Pancreatic acinar cell carcinoma (pACC) is a rare neoplasm of the exocrine pancreas. There is a dearth of information about tumor characteristics and patient outcomes. This study describes the clinical characteristics, genetic alterations, and survival outcomes of resected pACC.
View Article and Find Full Text PDFPhase 1 Study of Adjuvant Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Transduced Pancreatic Tumor Cell Vaccine, Low-Dose Cyclophosphamide, and Stereotactic Body Radiation Therapy Followed by FOLFIRINOX in High-Risk Resected Pancreatic Ductal Adenocarcinoma.
Int J Radiat Oncol Biol Phys
November 2024
Radiation Medicine, Zucker School of Medicine at Hofstra/Northwell, Lake Success, New York, New York.. Electronic address:
Purpose: Local and distant progression remains common following resection of resectable pancreatic ductal adenocarcinoma (PDAC) despite adjuvant multiagent chemotherapy. We report a prospective institutional phase 1 trial incorporating adjuvant GVAX vaccine, low-dose cyclophosphamide (Cy), and stereotactic body radiation therapy (SBRT) followed by FOLFIRINOX (FFX) among patients who underwent resection of high-risk PDAC.
Patients And Methods: The study design was a modified 3+3.
Adjuvant Modified FOLFIRINOX for Resected Pancreatic Adenocarcinoma (PDAC): Clinical Insights and Genomic Features from a Large Contemporary Cohort.
J Natl Cancer Inst
October 2024
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA.
Article Synopsis
- Adjuvant mFOLFIRINOX (mFFX) is a standard treatment for patients with resected pancreatic ductal adenocarcinoma (PDAC), but there is limited information on its effectiveness outside of clinical trials.
- A study of 147 patients showed a median recurrence-free survival (RFS) of 26 months, with some patients over 70 years experiencing a median overall survival (OS) of 51 months.
- Starting mFFX treatment within 8 weeks of surgery was linked to better survival outcomes, while certain genetic factors like KRAS mutations suggested poorer RFS and OS.
Consensus, debate, and prospective on pancreatic cancer treatments.
J Hematol Oncol
October 2024
Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans St, Baltimore, MD, 21287, USA.
Article Synopsis
- Pancreatic cancer is a highly aggressive disease, and despite advancements in treatment, patient prognosis has not significantly improved.
- Surgical strategies focus on achieving R0 resection in resectable cases, while the use of neoadjuvant therapy remains debated for those patients.
- Chemotherapy is the primary treatment for advanced cases, with ongoing investigations into immunotherapy and targeted therapies to enhance treatment effectiveness.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!